ABSTRACT
INTRODUCTION
Angiogenesis is the process whereby new blood vessels develop from the preexisting vasculature by migration and proliferation of endothelial cells (1) . It takes place physiologically during embryonic development, during the normal growth of tissues and the wound healing as well as during the growth, invasion and metastatic spread of malignant neoplasms (2) . A variety of humeral agents need to be activated to generate a neovascular blood supply or angiogenesis in the human body.
Vascular endothelial growth factor (VEGF) is one of the most important humeral agents need to be activated to ensure the growth of the vascular endothelium (3) . VEGF is a potent mediator that has been found to be implicated in the development of tumor growth by promoting angiogenesis (4) . VEGF is a heparinbinding glycoprotein that is secreted as a homodimer of 45 KD (5) . There are five different molecular species resulting from alternative splicing of the VEGF gene which, according to their number of amino acids, have been termed VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 (6) . VEGF165 is the predominant isoform secreted by a variety of normal and transformed cells whereas VEGF206 is rarely expressed (7) . The biological effects of VEGF are mediated by at least two tyrosine kinase receptors, kinase domain region (KDR) and fms-like tyrosine kinase 1 (flt-1) which bind VEGF with high affinity (8,9) . Both receptors are predominantly expressed in vascular endothelial cells (10) . Binding of VEGF to its receptors causes receptor dimeriation and activation of the intrinsic kinase followed by autophosphorylation of the receptor and subsequent signal transduction. There are significant differences with respect to biological relevance between KDR/flk-1 and flt-1. KDR/flk-1 but not flt-1 can mediate the mitogenic and chemotactic effects of VEGF and activate signaling pathways such as the mitogenactivated protein kinases in endothelial cells (11,12) . The aim of the present study is to detect the gene expression of m-RNA of VEGF as well as serum levels of its encoded polypeptide in patients with various liver diseases to assess whether they are correlated with different clinical, laboratory and histological parameters of these diseases. (14) . Liver biopsies were taken after a written consent from all patients who agreed to be members in the present study. The liver biopsies were immediately immersed in lysis buffer and stored at -80°C until required for RNA extraction and polymerase chain reaction (PCR).Blood samples were taken from all individuals included in the current work. Sera obtained by centrifugation of clotted blood samples and stored at -80°C until assayed.
PATIENTS & METHODS
RNA extraction: Total RNA was extracted from frozen liver biopsies according to the method of Chomczynski and Sacchi (15) , using QI amp RNA kit provided by Qiagen Inc, USA. The RNA was quantitated at 260 nm using UV spectrophotometer. Reverse transcriptase (RT-PCR) for VEGF: Reverse transcription (RT) of RNA was performed for detecting human VEGF using 2 µg of total RNA, 1µL (20 pmol) oligo (dT)18 primer and 0.8µL RNA reverse transcriptase for 60 minutes at 37°C . Each RT product was amplified by polymerase chain reaction (PCR). For amplification of VEGF a sense primer (5'-ATGGCAGAAGGAGGGCAGCAT-3') and an antisense primer (5'-TTGGTGAGGTTTGATCCGCATCA T-3') were generated. cDNAs were amplified by incubation of 4µL of RT product with 30.5µL water, 4µL 25mmol/L MgCl 2 , 1µL dNTP´s (10mM), 5µL 10x PCR buffer, 0.5µL (2.5U) Taq-DNAPolymerase and 2.5µL of each primer. Amplification conditions for 40 cycles were as follows: denaturation at 95°C for one minute, annealing at 55°C for one minute and extension at 72°C for two minutes.
Each PCR reaction product (10 µL) was run on a 1.5% agarose gel and visualized using ethidium bromide. The PCR product yielded a 255bp fragment. Densitometric analysis of PCR products was performed for semiquantitation of the amplified PCR products by using of a densitometer (Molecular Dynamics, Sunnyvale, CA, U.S.A. 
RESULTS
Results of the present study are shown in tables 1-8 and illustrated in figure 1. respectively, and all were significantly higher than control group (302.7±92.6), and the difference between groups was statistically significant at P <0.01 (Table 5) .
NS: non significant
VEGF m-RNA expression as well as its serum level were correlated significantly with serum albumin only in cirrhotic patients (r = 0.612 and r = 0.577 respectively). There was a significant positive correlation between the serum VEGF level and platelet count in HCC patients (r = 0.421) and negative correlation was observed between VEGF levels and platelet count in other patient groups and this correlation was highly significant in patients with chronic hepatitis (r = -0.646). Among patients with HCC no significant difference was noted between VEGF levels and grades of tumor (P >0.05), and, also, no significant correlation was observed between VEGF m-RNA expression as well as its serum level and AFP (r = 0.117 and r = 0.146 respectively). In group of chronic hepatitis C no significant difference was found between VEGF and degrees of fibrosis (P >0.05).
DISCUSSION
Hepatocellular carcinoma (HCC) is the third largest cause of cancerrelated death behind only lung and colon cancers. HCC is a highly vascular tumor that expresses VEGF (16) .
VEGF is known to play an important role not only in the angiogenesis of different human tumors but, also, in physiological and non-malignant pathological conditions 17) .In addition, increasing evidence indicates that hypoxia and VEGFinduced angiogenesis may, also, contribute to wound healing and tissue repair (18) . It has been shown that the VEGF level in serum is of value for predicting disease progression and prognosis in different cancers, such as the gastrointestinal, breast, lung, urothelium, ovary, and lymphoma (19) . Expression of VEGF m-RNA in serum might not always correlate significantly with the gene expression level in tumor tissues (20) , therefore; liver tissue was used for measurement of VEGF m-RNA instead of serum in the present study. However, compared with expression in tumor tissue, the advantage of measurement of serum VEGF level is that it can be performed without tissue specimens and repeated (21) . According to Jeng et al. (19) for more accuracy; we chose to measure m-RNA expression of VEGF in liver tissue in addition to its encoded polypeptide level in serum.
In the present study, there was a statistically significant over-expression of VEGF m-RNA in patients with hepatocellular carcinoma as compared to patients with chronic hepatitis and patients with liver cirrhosis that showed minimal VEGF m-RNA expression. Patients with HCC showed the highest elevation in VEGF levels (p<0.001).
These findings are in agreement with those of Poon et al.
(22) and Iavarone et al.
(4) who found that the VEGF concentration was elevated in patients with HCC and could be a new marker predicting angiogenesis, invasion, metastasis and prognosis of HCC. In addition to its known angiogenic properties, VEGF may promote HCC spreading into normal liver parenchyma (23) . The results of the current study are highly supported by the findings of Brodsky et al.
(24) who reported that one of the major stimuli for angiogenesis in these liver diseases could be VEGF as the VEGF expression was higher in HCC and diminished in cirrhotic nodules, thus strongly correlating with the degree of vascularization.
The exact mechanism of increased VEGF in HCC is not clear but the production of VEGF by HCC cells could be explained on the basis that regions of low oxygen (hypoxia) and necrosis are common features of solid tumors and a marked elevation in VEGF expression in tumor cells around necrotic areas has been suggested in some neoplasms (25) . Therefore, hypoxia may play a central role in VEGF upregulation in HCC (6) . Several lines of evidence indicate that enhanced VEGF expression in response to hypoxia is due to transcriptional activation (26) as well as m-RNA stabilization (27) . In addition, an internal ribosome entry site ensures efficient translation of VEGF m-RNA, even under hypoxic conditions (28) . The current study showed that patients with liver cirrhosis elicited a significant reduction of tissue VEGF as compared to CHC patients (p<0.01). VEGF expression in liver cirrhosis has been suggested to result from proinflammatory cytokines released by infiltrating lymphocytes. .While others found low serum VEGF level in liver cirrhosis, they attributed this to low platelet count found in cirrhotic patients (35, 36) . A significant correlation was found between serum albumin and VEGF levels only in cirrhotic patients. These findings disagreed with those of Assy et al.
(43) who reported that VEGF levels reflect neither hepatic synthetic function nor inflammatory activity and suggested that serum VEGF is not the result of damaged hepatocytes but rather a high regenerative capacity. Conclusion: Gene expression of m-RNA of VEGF and its encoded polypeptide level were highly overexpressed in HCC and diminished in LC, so its measurement is highly recommended for early detection of malignant transformation of LC to HCC and makes VEGF one of the most important markers of HCC. Moreover, the HCV was able to activate the expression of VEGF in chronic hepatitis C patients. 
